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Objectives: Obesity is a serious health problem in worldwide, which is think the result
of genetic and environmental factors, especially an inappropriate lifestyle, character-
ized by high fat diet and physical inactivity. Obesity, insulin resistance and dyslipi-
demia often occur in concert, which in partly contribute to cardiovascular disease.
Physical exercise strongly encouraged for obese people due to physical inactivity is an
important contributor to the development of cardiovascular disease. Fibroblast growth
factor -21 (FGF-21) is a cytokine closely related to the glucose and lipid metabolism,
which is an important member of the ﬁbroblast growth factor family was found in
recent years, it mainly secreted by the liver and adipose tissue. it was recently shown
that FGF-21 levels were positively associated with physical activity levels in healthy
non obese people. Regular exercise also plays an important role in improving the level
of FGF-21. Recent research has also found that acute exercise can increase the level of
plasma FGF-21 and promote fat decomposition, improve insulin sensitivity in healthy
subjects. In the light of the improved insulin sensitivity by exercise depends in a large
extent on acute effects of exercise, acute exercise has been reported to play an
important role in improved glucose and lipid metabolism. However, whether acute
exercise inﬂuence FGF-21 level in obesity, and FGF-21 involved in the metabolism of
glucose and lipid process were unclear. To study the changes of plasma FGF-21,
blood glucose, serum insulin, free fatty acids after acute exercise in male obese youth,
in order to investigate acute effect of exercise on obese plasma FGF-21 and mecha-
nism regulated lipid.
Methods: Simple obesity male students (OG, n¼10) and healthy non obese male
students (CG, n¼10) take 2 different intensity exercise test (VO2max 50% vs VO2max
75%) respectively, the venous blood was collected in a quiet state, immediately after
exercise, 30min, 60min and120min. the plasma FGF-21, blood glucose, blood insulin
and free fatty acid levels were detected.
Results: The AUC of FGF-21 were negatively correlated with AUC of insulin after
two acute exercise in CG (r¼-0.613, P¼0.004), and positively correlated with AUC of
FFA (r¼0.536, P¼0.015) after two acute exercise, in addition, the AUC of FGF-21
were positively correlated with AUC of FFA (r¼0.568, P¼0.009) after two acute
exercise in OG.
Conclusions: There is a certain degree of FGF-21 resistance in obese young men. And
the response of FGF-21 to acute exercise is reduced in male obese youth compare with
healthy subjects; the increased level of FGF-21 may mediate glucose and lipid
metabolism regulated by acute exercise in healthy subjects, although the glyco-
metabolism was not inﬂuenced by increased FGF-21 induced by acute exercise, but
may contribute to their fat decomposition in male obese youth.Cardiovascular Disease Clinical Research
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Objectives: To perform a double-blinded, randomized, placebo-controlled trial to
determine the impact of CD133+ bone marrow cells (BMC) on left ventricular (LV)
function and clinical symptoms.
Methods: 70 patients with chronic ischaemic heart disease and impaired LV function
(left ventricular ejection fraction, LVEF <35%) were randomized (1:1) to inject
autologous CD133+ BMC and placebo in the non-transmural, hypokinetic infarct
border zone. Pre-operative LVEF was 297% in CD133+ patients and 286% in
placebo patients. Outcome was assessed after 6 months, and the primary endpoint was
LVEF measured by cardiac magnetic resonance imaging (MRI) at rest.
Results: There was no difference in 5-min walking distance between groups at follow-
up, and New York Heart Association class improved more in the placebo group (P ¼
0.004). CD133+ BMC treated patients showed a better recovery of regional wall
motion when the target area was posterior by echocardiography. By cardiac MRI,
LVEF at 6 months was 358% in the placebo group and 337% in BMC group (P ¼
0.42), with an average inter-group difference of -2.4% (95% CI -6.2-2.6). Systolic or
diastolic LV volume at 6 months was not different. In the CD133+ group, myocardialC116 JACC Vol 64/16/Suppl C j October 16–1perfusion at rest recovered better in LV segments than in the placebo group (10 vs.
3%, P<0.001). Scar mass decreased by 2.56 g in CD133+ patients (P ¼ 0.05), but
was unchanged in the placebo group (0.46 g, P ¼ 0.6; inter-group difference in
change ¼ 2.5 g (95% CI -1.5-4.8)).
Conclusions: Although there may be some improvements in scar size and regional
perfusion, intra-myocardial injection of CD133+ BMC has no effect on global LVEF
and clinical symptoms.
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Objectives: To evaluate the effectiveness and safety of CSWT for treatment of CAD
patients without coronary artery revascularization.
Methods: A total of 87 CAD patients without coronary artery revascularization
were enrolled in this study, 68 male and 19 female, aged from 43 to 80 years
(66.808.41 years). The patients were divided into three group by using randomised
single-blind method, Group A enrolled 32 cases (received 9 spots treatment of each
ischemia target region), Group B enrolled 30 cases (received 25 spots treatment of
each ischemia target region). In the course of 3 months, nine CSWT procedures were
performed in all of the patients. And 25 patients were in Group C (treated with the
same procedures but without the shock wave energy). Before the CSWT (0 month)
and the follow-up of 3 months, 6 months, 12 months, Patients of three groups were
received the examinations include the 99mTc-MIBI myocardial perfusion and 18F-
FDG myocardial metabolism SPECT to identify the myocardial ischemia and viability
segments. Canadian Cardiovascular Society (CCS) angina scale, New York Heart
Association (NYHA) class, Seattle Angina Questionnaire (SAQ) scale, nitroglycerin
used dosage, 6-min walk test (6MWT), Left ventricular ejection fraction (LVEF), left
ventricular end diastolic dimension (LVEDD) and so on to evaluate the effect of
CSWT.
Results: During the CSWT, the angina of the patients was not to be worse and no
heart failure, no hemorrhage, no embolism, no malignant arrhythmia (ventricular
tachycardia/ﬁbrillation), no myocardial necrosis as well as no any obvious changes on
blood pressure, heart rate and blood oxygen saturation. In follow-up from 3 months to
12 months, the NYHA class, CCS angina scale, SAQ scale, 6MWT and nitroglycerin
used dosage in group A and group B improved signiﬁcantly compared with group C
(P<0.05). Follow-up to 6 months, the above mentioned parameters of group B
improved signiﬁcantly than group A (P<0.05). LVEF of the group B at 12 months
follow-up improved signiﬁcantly compared with group A (P<0.05). The differences
of LVEF in group C have no statistical signiﬁcance (P>0.05). However, follow-up to
12 months LVEDD in group C signiﬁcant enlarged than 0 month (P<0.05). During
follow-up, the myocardial ischemic segments, dysbolism segments, total radioactive
score of perfusion imaging, total radioactive score of metabolism imaging of group A
and group B improved signiﬁcantly compared with group C (P<0.05), and the above
mentioned parameters of group B improved signiﬁcantly than group A (P<0.05).
Follow-up to 12 months the above mentioned parameters of group C signiﬁcant worse
than the baseline value (P<0.05).
Conclusions: (1) CSWT is a non-invasive, safe, effective, easy to duplicate, new
method to promote myocardial angiogenesis. (2) CSWT could relieve myocardial
ischemia related symptoms in the early stage, improved myocardial perfusion and
metabolism, increased the coronary artery reserve, life quality and exercise tolerance
increased too, it can restrain cardiac remodeling and improved the heart function. (3)
CSWT could use for the end-stage or non-end-stage CAD patients who have not
received revascularization treatment. (4) It seems that expanding the range of treat-
ment could obvious improve myocardial perfusion, myocardial metabolism and heart
function than the conventional treatment protocols.
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Objectives: This meta-analysis aims to evaluate the efﬁcacy of mesenchymal stem
cells (MSCs) therapy in patients with acute myocardial infarction.
Methods: A random-effects meta-analysis was performed on randomized controlled
trials (RCTs) investigating the effects of MSCs therapy in patients with acute
myocardial infarction that were published from January 2000 to January 2014. The
end points were left ventricular (LV) ejection fraction, LV end-systolic and end-dia-
stolic volumes, infarct size, and major adverse cardiac and cerebrovascular event rates.
Results: Combining the results of 28 RCTs, LV ejection fraction increased by +2.25%
(95% conﬁdence interval [CI], 0.68-3.52; P<0.01) in the MSCs group as compared
with controls, evoked by a preservation of LV end-systolic volume (-4.05 mL; 95% CI
-6.91- -1.18; P<0.01) and a reduction in infarct size (-2.69%; 95% CI -4.83- -0.56;
P<0.01). There is no effect on cardiac function, volumes, or infarct size in RCTs
(n¼11) that used magnetic resonance imaging (MRI) -derived end points. No9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
